The right ventricle in pulmonary hypertension: From dogma to data

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 5, 2010, Pages 586-588

  Hemnes, Anna R ^a   Kawut, Steven M ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

DRUG EFFECT; EDITORIAL; ENDURANCE TRAINING; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE; COMORBIDITY; HUMAN; NOTE; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT;

COMORBIDITY; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; RISK ASSESSMENT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 77957698333     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201006-0892ED     Document Type: Editorial

References (18)

1. van Wolferen SA, Boonstra A, Marcus JT, Marques KM, Bronzwaer JG, Postmus PE, Vonk-Noordegraaf A. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006;92:1860-1861. (Pubitemid 44851345)
2. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, Rosenzweig EB, Kerstein D, Barst RJ. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95:199-203.
3. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier J, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
5. Bloomfield RA, Lauson HD, Cournand A, Breed ES, Richards DW. Recording of right heart pressures in normal subjects and in patients with chronic pulmonary disease and various types of cardio-circulatory disease. J Clin Invest 1946;25:639-664.
6. Cournand A, Riley RL, Breed ES, Baldwin ED, Richards DW, Lester MS, Jones M. Measurement of cardiac output in man using the technique of catheterization of the right auricle or ventricle. J Clin Invest 1945;24:106-116.
7. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
8. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120-126.
9. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1269-1275.
10. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658. (Pubitemid 32479962)
11. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
12. Handoko M, de Man F, Allgart C, Paulus W, Westerhof N, Vonk-Noordegraaf A. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. European Respiratory Review 2010;19:72-82.
13. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K. Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J 2009;73:2337-2341.
14. Handoko M, deMan F, van Ballegoij J, Schalij I, Westerhof N, van der Velden J, Paulus W, vonk Noordegraaf A. Chronic treatment with low-dose bisoprolol improves survival and cardiac function in experimental pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med; 2010;181:A4896.
15. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182:652-660.
16. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:238-248.
17. Handoko ML, Lamberts RR, Redout EM, deMan FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, Vonk-Noordegraaf A. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol 2009;297:H1752-H1759.
18. Handoko ML, de Man FS, Happe CM, Schalij I, Musters RJ, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk-Noordegraaf A. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120:42-49.